ZENTALIS PHARMACEUTICALS INC (ZNTL) Fundamental Analysis & Valuation

NASDAQ:ZNTL • US98943L1070

Current stock price

2.62 USD
+0.06 (+2.34%)
At close:
2.63 USD
+0.01 (+0.38%)
After Hours:

This ZNTL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ZNTL Profitability Analysis

1.1 Basic Checks

  • In the past year ZNTL has reported negative net income.
  • ZNTL had a negative operating cash flow in the past year.
  • In the past 5 years ZNTL always reported negative net income.
  • ZNTL had a negative operating cash flow in each of the past 5 years.
ZNTL Yearly Net Income VS EBIT VS OCF VS FCFZNTL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

  • ZNTL has a Return On Assets (-45.48%) which is in line with its industry peers.
  • ZNTL has a Return On Equity (-58.86%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -45.48%
ROE -58.86%
ROIC N/A
ROA(3y)-45.14%
ROA(5y)-40.51%
ROE(3y)-56.86%
ROE(5y)-50.48%
ROIC(3y)N/A
ROIC(5y)N/A
ZNTL Yearly ROA, ROE, ROICZNTL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

  • ZNTL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZNTL Yearly Profit, Operating, Gross MarginsZNTL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -50K -100K -150K -200K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. ZNTL Health Analysis

2.1 Basic Checks

  • ZNTL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ZNTL has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, ZNTL has more shares outstanding
  • There is no outstanding debt for ZNTL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ZNTL Yearly Shares OutstandingZNTL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ZNTL Yearly Total Debt VS Total AssetsZNTL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • ZNTL has an Altman-Z score of -3.96. This is a bad value and indicates that ZNTL is not financially healthy and even has some risk of bankruptcy.
  • ZNTL has a Altman-Z score (-3.96) which is comparable to the rest of the industry.
  • ZNTL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.96
ROIC/WACCN/A
WACC9.03%
ZNTL Yearly LT Debt VS Equity VS FCFZNTL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

  • A Current Ratio of 7.76 indicates that ZNTL has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 7.76, ZNTL is in the better half of the industry, outperforming 71.78% of the companies in the same industry.
  • A Quick Ratio of 7.76 indicates that ZNTL has no problem at all paying its short term obligations.
  • ZNTL's Quick ratio of 7.76 is fine compared to the rest of the industry. ZNTL outperforms 72.17% of its industry peers.
Industry RankSector Rank
Current Ratio 7.76
Quick Ratio 7.76
ZNTL Yearly Current Assets VS Current LiabilitesZNTL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. ZNTL Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 25.87% over the past year.
  • Looking at the last year, ZNTL shows a very negative growth in Revenue. The Revenue has decreased by -33.76% in the last year.
EPS 1Y (TTM)25.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.93%
Revenue 1Y (TTM)-33.76%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • ZNTL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.91% yearly.
  • The Revenue is expected to grow by 31.87% on average over the next years. This is a very strong growth
EPS Next Y11.5%
EPS Next 2Y7.94%
EPS Next 3Y8.44%
EPS Next 5Y11.91%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-32.89%
Revenue Next 5Y31.87%

3.3 Evolution

ZNTL Yearly Revenue VS EstimatesZNTL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2024 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
ZNTL Yearly EPS VS EstimatesZNTL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. ZNTL Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ZNTL. In the last year negative earnings were reported.
  • Also next year ZNTL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZNTL Price Earnings VS Forward Price EarningsZNTL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZNTL Per share dataZNTL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.94%
EPS Next 3Y8.44%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ZNTL Dividend Analysis

5.1 Amount

  • ZNTL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ZNTL Fundamentals: All Metrics, Ratios and Statistics

ZENTALIS PHARMACEUTICALS INC

NASDAQ:ZNTL (3/20/2026, 8:00:03 PM)

After market: 2.63 +0.01 (+0.38%)

2.62

+0.06 (+2.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-24
Inst Owners56.86%
Inst Owner Change-22.23%
Ins Owners2.29%
Ins Owner Change-0.27%
Market Cap189.29M
Revenue(TTM)26.86M
Net Income(TTM)-148.84M
Analysts77.33
Price Target4.9 (87.02%)
Short Float %6.73%
Short Ratio2.57
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)34.44%
Min EPS beat(2)31.28%
Max EPS beat(2)37.6%
EPS beat(4)4
Avg EPS beat(4)24.17%
Min EPS beat(4)13.88%
Max EPS beat(4)37.6%
EPS beat(8)7
Avg EPS beat(8)26.27%
EPS beat(12)9
Avg EPS beat(12)13.53%
EPS beat(16)11
Avg EPS beat(16)12.04%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-9.65%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-35.71%
EPS NY rev (1m)0%
EPS NY rev (3m)-8.48%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.05
P/FCF N/A
P/OCF N/A
P/B 0.75
P/tB 0.75
EV/EBITDA N/A
EPS(TTM)-1.92
EYN/A
EPS(NY)-1.9
Fwd EYN/A
FCF(TTM)-1.86
FCFYN/A
OCF(TTM)-1.86
OCFYN/A
SpS0.37
BVpS3.5
TBVpS3.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -45.48%
ROE -58.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.14%
ROA(5y)-40.51%
ROE(3y)-56.86%
ROE(5y)-50.48%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.76
Quick Ratio 7.76
Altman-Z -3.96
F-Score3
WACC9.03%
ROIC/WACCN/A
Cap/Depr(3y)79.15%
Cap/Depr(5y)368.78%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.93%
EPS Next Y11.5%
EPS Next 2Y7.94%
EPS Next 3Y8.44%
EPS Next 5Y11.91%
Revenue 1Y (TTM)-33.76%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-32.89%
Revenue Next 5Y31.87%
EBIT growth 1Y26.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year27.07%
EBIT Next 3Y8.71%
EBIT Next 5YN/A
FCF growth 1Y34.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.34%
OCF growth 3YN/A
OCF growth 5YN/A

ZENTALIS PHARMACEUTICALS INC / ZNTL Fundamental Analysis FAQ

What is the ChartMill fundamental rating of ZENTALIS PHARMACEUTICALS INC (ZNTL) stock?

ChartMill assigns a fundamental rating of 3 / 10 to ZNTL.


What is the valuation status of ZENTALIS PHARMACEUTICALS INC (ZNTL) stock?

ChartMill assigns a valuation rating of 0 / 10 to ZENTALIS PHARMACEUTICALS INC (ZNTL). This can be considered as Overvalued.


Can you provide the profitability details for ZENTALIS PHARMACEUTICALS INC?

ZENTALIS PHARMACEUTICALS INC (ZNTL) has a profitability rating of 1 / 10.


What is the earnings growth outlook for ZENTALIS PHARMACEUTICALS INC?

The Earnings per Share (EPS) of ZENTALIS PHARMACEUTICALS INC (ZNTL) is expected to grow by 11.5% in the next year.